Effect of interferon-α-2b and interleukin-2 combined with chemotherapy in metastatic melanoma.

IF 4.3 4区医学 0 MEDICINE, GENERAL & INTERNAL

Panminerva medica Pub Date : 2024-06-01 Epub Date: 2020-07-22 DOI:10.23736/S0031-0808.20.03912-9

Zheng Su, Fen Shi, Jian Zhang, Weiqiang Liang

{"title":"Effect of interferon-α-2b and interleukin-2 combined with chemotherapy in metastatic melanoma.","authors":"Zheng Su, Fen Shi, Jian Zhang, Weiqiang Liang","doi":"10.23736/S0031-0808.20.03912-9","DOIUrl":null,"url":null,"abstract":"Background: To explore the efficacy and safety of interferon-α-2b and interleukin-2 combined with chemotherapy in treating patients with metastatic melanoma.Methods: The patients with metastatic melanoma in control group (N.=52) were treated with conventional DDAVC chemotherapy regimen, while those in combination group (N.=52) received biotherapy with interferon-α-2b and interleukin-2 in addition to the chemotherapy in control group. At the end of the treatments, the serum immune function indicators, short-term efficacy and incidence of adverse reactions were compared between the two groups of patients, and patient's survival was followed up and recorded.Results: At 1 week after treatment, it was found that the overall response rate in combination group was substantially higher than that in control group (P=0.027). Besides, according to the serologic test results at 1 week after the chemotherapy, T lymphocyte subset activity was enhanced in patients in combination group compared with that before chemotherapy, with no statistically significant difference (P>0.05), but it was notably weakened in control group in comparison with that before chemotherapy (P<0.05). Finally, it was discovered through the log-rank test that the overall survival (OS) rate in combination group was remarkably superior to that in control group (P=0.029), but there was no statistically significant difference in the progression-free survival (PFS) rate between the two groups (P=0.076).Conclusions: Compared with chemotherapy alone, interferon-α-2b and interleukin-2 combined with chemotherapy can raise the clinical short-term efficacy and long-term OS rate in the patients with metastatic melanoma and alleviate their toxic side reactions, with higher safety.","PeriodicalId":19851,"journal":{"name":"Panminerva medica","volume":" ","pages":"131-136"},"PeriodicalIF":4.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Panminerva medica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S0031-0808.20.03912-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/7/22 0:00:00","PubModel":"Epub","JCR":"0","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To explore the efficacy and safety of interferon-α-2b and interleukin-2 combined with chemotherapy in treating patients with metastatic melanoma.

Methods: The patients with metastatic melanoma in control group (N.=52) were treated with conventional DDAVC chemotherapy regimen, while those in combination group (N.=52) received biotherapy with interferon-α-2b and interleukin-2 in addition to the chemotherapy in control group. At the end of the treatments, the serum immune function indicators, short-term efficacy and incidence of adverse reactions were compared between the two groups of patients, and patient's survival was followed up and recorded.

Results: At 1 week after treatment, it was found that the overall response rate in combination group was substantially higher than that in control group (P=0.027). Besides, according to the serologic test results at 1 week after the chemotherapy, T lymphocyte subset activity was enhanced in patients in combination group compared with that before chemotherapy, with no statistically significant difference (P>0.05), but it was notably weakened in control group in comparison with that before chemotherapy (P<0.05). Finally, it was discovered through the log-rank test that the overall survival (OS) rate in combination group was remarkably superior to that in control group (P=0.029), but there was no statistically significant difference in the progression-free survival (PFS) rate between the two groups (P=0.076).

Conclusions: Compared with chemotherapy alone, interferon-α-2b and interleukin-2 combined with chemotherapy can raise the clinical short-term efficacy and long-term OS rate in the patients with metastatic melanoma and alleviate their toxic side reactions, with higher safety.

查看原文本刊更多论文

干扰素-α-2b和白细胞介素-2联合化疗对转移性黑色素瘤的疗效。

背景：探讨干扰素-α-2b和白介素-2联合化疗治疗转移性黑色素瘤患者的有效性和安全性：探讨干扰素-α-2b和白细胞介素-2联合化疗治疗转移性黑色素瘤患者的有效性和安全性：方法：对照组（52例）转移性黑色素瘤患者接受常规DDAVC化疗方案治疗，联合组（52例）患者在对照组化疗的基础上接受干扰素-α-2b和白细胞介素-2的生物治疗。治疗结束后，比较两组患者的血清免疫功能指标、短期疗效和不良反应发生率，并随访和记录患者的生存情况：治疗 1 周后发现，联合组的总反应率大大高于对照组（P=0.027）。此外，根据化疗后 1 周的血清学检测结果，联合组患者的 T 淋巴细胞亚群活性较化疗前增强，差异无统计学意义（P>0.05），但对照组较化疗前明显减弱（PConclusions：与单纯化疗相比，干扰素α-2b和白细胞介素-2联合化疗可提高转移性黑色素瘤患者的临床短期疗效和长期OS率，减轻其毒副反应，安全性更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Panminerva medica 医学-医学：内科

CiteScore

5.00

自引率

2.30%

发文量

199

审稿时长

>12 weeks

期刊介绍： Panminerva Medica publishes scientific papers on internal medicine. Manuscripts may be submitted in the form of editorials, original articles, review articles, case reports, special articles, letters to the Editor and guidelines. The journal aims to provide its readers with papers of the highest quality and impact through a process of careful peer review and editorial work. Duties and responsibilities of all the subjects involved in the editorial process are summarized at Publication ethics. Manuscripts are expected to comply with the instructions to authors which conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Editors by the International Committee of Medical Journal Editors (ICMJE).